Clinical significance of RBM3 expression in surgically treated colorectal lung metastases and paired primary tumours

Research output: Contribution to journalArticlepeer-review

Abstract

Background The lungs are the second most common site of metastases in colorectal cancer (CRC). The aim of this study was to investigate prognostic factors, including RNA‐binding motif protein 3 (RBM3) expression, in patients with CRC treated with pulmonary metastasectomy (PM). Methods The cohort included all patients treated with PM at Skåne University Hospital, Lund, Sweden, from 2000 to 2014. Clinicopathological, treatment, and survival data were collected. Immunohistochemical staining of RBM3 was evaluated on tissue microarrays with samples from all lung metastases and a subset of paired primary tumors. Kaplan–Meier analysis and Cox proportional hazards modeling were applied to examine the associations of investigative factors with overall survival (OS) and recurrence‐free survival. Results In total, 216 patients with a primary tumor in the rectum (57%), left colon (34%), or right colon (9%) underwent PM. The 5‐year OS rate was 56%. Age > 60 years, more than one metastasis, size of metastasis > 3 cm, disease‐free interval < 24 months, low RBM3 score in the lung metastasis, and no adjuvant chemotherapy following PM were prognostic factors for shorter OS. Conclusions Several prognostic factors, including RBM3 expression, may be of aid in selecting CRC patients with lung metastases for PM as well as adjuvant therapy.
Original languageEnglish
Pages (from-to)1144-1156
JournalJournal of Surgical Oncology
Volume123
Issue number4
DOIs
Publication statusPublished - 2021 Mar 15

Subject classification (UKÄ)

  • Cancer and Oncology

Fingerprint

Dive into the research topics of 'Clinical significance of RBM3 expression in surgically treated colorectal lung metastases and paired primary tumours'. Together they form a unique fingerprint.

Cite this